Omeros (NASDAQ:OMER) Hits New 52-Week High – Here’s What Happened

Shares of Omeros Corporation (NASDAQ:OMER) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $17.65 and last traded at $15.0850, with a volume of 24509175 shares. The stock had previously closed at $8.75.

Omeros News Roundup

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: FDA granted Omeros its first-ever approval for YARTEMLEA, giving the company an exclusive indication in TA‑TMA — a clear catalyst for revenue and re‑rating expectations. Omeros scores its first-ever FDA nod for stem cell transplant drug Yartemlea
• Positive Sentiment: Omeros scheduled an investor conference call to discuss the YARTEMLEA approval (moved to Jan 7) to ensure broad participation — a sign management plans to actively communicate commercialization and timing details. Omeros Announces New Date for YARTEMLEA® Approval Conference Call
• Positive Sentiment: Coverage explaining why OMER “skyrocketed” points directly to the FDA approval and the ensuing shift in investor expectations for revenue and pipeline value. Why Omeros Stock Skyrocketed Today
• Positive Sentiment: D. Boral Capital reiterated a Buy rating for OMER, which supports bullish sentiment among investors following the regulatory win. D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER)
• Neutral Sentiment: Unusually large options volume was reported around OMER, indicating speculative positioning and hedging activity that can amplify intraday moves. Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)
• Neutral Sentiment: Analysts and market writers are revisiting Omeros’ valuation after a multi‑year repricing; longer‑term expectations and assumptions about commercialization will shape future moves. Omeros (OMER): Revisiting Valuation After a Powerful Multi‑Year Share Price Repricing
• Neutral Sentiment: Omeros is highlighted on investor radars alongside other names — increased attention can sustain higher volume but also greater volatility. Nike, Omeros Corporation, Micron Technology, Intel And Dynavax Technologies: Why These 5 Stocks Are On Investors’ Radars Today
• Neutral Sentiment: Broader commentary on health innovations cites recent drug approvals (contextual industry coverage rather than company‑specific new data). Health Innovations: From Social Media Warnings to Groundbreaking Drug Approvals
• Negative Sentiment: Some pre‑market sessions showed OMER moving lower with other biotech names, reflecting short‑term profit‑taking or broader market headwinds that can offset approval‑driven gains. Biohaven, Omeros And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. WBB Securities reissued a “strong-buy” rating and issued a $45.00 target price on shares of Omeros in a research report on Wednesday, October 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $33.67.

Omeros Price Performance

The firm’s 50 day moving average price is $9.06 and its 200-day moving average price is $5.81. The stock has a market cap of $1.11 billion, a P/E ratio of -7.78 and a beta of 2.48.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. On average, analysts expect that Omeros Corporation will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

Large investors have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. bought a new position in Omeros during the 2nd quarter valued at about $32,000. Harbour Investments Inc. lifted its holdings in shares of Omeros by 46.1% during the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 4,251 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Omeros by 829.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,971 shares during the last quarter. Sei Investments Co. bought a new stake in shares of Omeros in the second quarter worth $40,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 5,677 shares during the period. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.